515 related articles for article (PubMed ID: 9031111)
21. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.
Lickliter JD; Begley CG; Boyd AW; Szer J; Grigg AP
Leuk Lymphoma; 1994 Sep; 15(1-2):91-7. PubMed ID: 7532059
[TBL] [Abstract][Full Text] [Related]
22. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Cortelazzo S; Viero P; Bellavita P; Rossi A; Buelli M; Borleri GM; Marziali S; Bassan R; Comotti B; Rambaldi A
J Clin Oncol; 1995 Apr; 13(4):935-41. PubMed ID: 7535843
[TBL] [Abstract][Full Text] [Related]
23. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Kröger N; Zeller W; Fehse N; Hassan HT; Krüger W; Gutensohn K; Lölliger C; Zander AR
Br J Haematol; 1998 Sep; 102(4):1101-6. PubMed ID: 9734664
[TBL] [Abstract][Full Text] [Related]
24. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
[TBL] [Abstract][Full Text] [Related]
25. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
[TBL] [Abstract][Full Text] [Related]
26. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
Bastion Y; Brice P; Haioun C; Sonet A; Salles G; Marolleau JP; Espinouse D; Reyes F; Gisselbrecht C; Coiffier B
Blood; 1995 Oct; 86(8):3257-62. PubMed ID: 7579423
[TBL] [Abstract][Full Text] [Related]
27. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
[TBL] [Abstract][Full Text] [Related]
28. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
[TBL] [Abstract][Full Text] [Related]
29. High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
Blystad AK; Holte H; Kvaløy S; Smeland E; Delabie J; Kvalheim G
Bone Marrow Transplant; 2001 Nov; 28(9):849-57. PubMed ID: 11781645
[TBL] [Abstract][Full Text] [Related]
30. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
31. A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
Laporte JP; Yeshurun M; Fouillard L; Labopin M; Cailliot C; Lesage S; Isnard F; Najman A; Gorin NC
Leukemia; 2004 Oct; 18(10):1717-21. PubMed ID: 15295607
[TBL] [Abstract][Full Text] [Related]
32. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
33. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma.
Watts MJ; Sullivan AM; Jamieson E; Pearce R; Fielding A; Devereux S; Goldstone AH; Linch DC
J Clin Oncol; 1997 Feb; 15(2):535-46. PubMed ID: 9053475
[TBL] [Abstract][Full Text] [Related]
34. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Jantunen E; Kuittinen T; Nousiainen T
Leuk Lymphoma; 2003 Jul; 44(7):1151-8. PubMed ID: 12916867
[TBL] [Abstract][Full Text] [Related]
35. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
36. High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.
Long GD; Chao NJ; Hu WW; Negrin RS; Wong RM; Blume KG
Cancer; 1996 Dec; 78(12):2502-9. PubMed ID: 8952558
[TBL] [Abstract][Full Text] [Related]
37. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
38. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
[TBL] [Abstract][Full Text] [Related]
39. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Knudsen LM; Gaarsdal E; Jensen L; Nielsen KJ; Nikolaisen K; Johnsen HE
J Hematother; 1996 Aug; 5(4):399-406. PubMed ID: 8877715
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
